title: Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials.
authors.forename: Domenica
authors.initials: D
authors.lastname: Lorusso
authors.forename: S
authors.initials: S
authors.lastname: Mainenti
authors.forename: G
authors.initials: G
authors.lastname: Ferrandina
authors.forename: G
authors.initials: G
authors.lastname: Scambia
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy / Q000523:psychology / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic / Q000523:psychology*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015337:Multicenter Studies as Topic / Q000523:psychology*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000523:psychology* / Q000601:surgery; D010052:Ovariectomy; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011788:Quality of Life; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin